Protecting the Heart and the Wallet: India Reaffirms Strict Price Caps on Cardiac Stents

NEW DELHI — In a decisive move to curb the rising costs of life-saving cardiac care, the Indian Central Government has officially reaffirmed its commitment to strict price ceilings on coronary stents. During a recent Lok Sabha session, the Ministry of Chemicals and Fertilizers tasked state governments with intensified oversight of private hospitals following reports of “hidden” overcharging and inflated implantation fees.

As cardiovascular disease (CVD) continues to claim more lives in India than any other non-communicable condition, the government’s stance serves as a critical intervention for millions of patients. While the National Pharmaceutical Pricing Authority (NPPA) sets the national price caps, the responsibility for ground-level enforcement now rests squarely with state authorities and Union Territories.

The Current Landscape of Stent Pricing

Coronary stents—tiny mesh tubes used to open clogged arteries—are classified as “essential medicines” under Schedule-I of the Drugs (Prices Control) Order, 2013. This classification allows the NPPA to fix “ceiling prices” that no manufacturer, importer, or hospital can legally exceed.

Following a marginal 1.74% adjustment linked to the Wholesale Price Index (WPI) in April 2025, the current maximum prices (excluding GST) are:

• Bare Metal Stents (BMS): ₹10,692.69

• Drug-Eluting Stents (DES): ₹38,933.14 (includes bioresorbable variants)

A Decade of Drastic Reductions

The significance of these figures is best understood by looking back. Before 2017, a high-end DES could cost a patient upwards of ₹2 lakh. The landmark 2017 intervention slashed these prices by roughly 85%, a move that the government describes as a “pro-people” step toward universal healthcare.

Why the Reaffirmation? Addressing “Procedure Creep”

The latest government push was triggered by inquiries from Member of Parliament Giridhari Yadav, who highlighted a disturbing trend: while stent prices are capped, some private hospitals are allegedly hiking “procedure charges” to compensate for lost margins.

Minister of State for Chemicals and Fertilizers, Anupriya Patel, emphasized that while the NPPA monitors the price of the device itself, the overall billing of medical services falls under the Clinical Establishments Act, 2010. States that have adopted this Act have the power to penalize hospitals that fail to display rates or those that engage in exploitative billing.

“The stent is a regulated drug, but the surgery is a service,” explains a veteran healthcare administrator. “The challenge lies in the ‘bundling’ of fees, where the stent is billed correctly, but the cost of the balloon, catheter, or even the room rent is inflated to offset the cap.”

Reports indicate that an angioplasty in a high-end private facility can still range between ₹2 lakh and ₹4.5 lakh, compared to ₹75,000 to ₹1.5 lakh in government-run institutions.

India’s Growing Cardiovascular Crisis

The urgency behind these regulations is driven by sobering statistics. India is currently facing a CVD epidemic, with over 63% of all deaths in the country linked to non-communicable diseases.

According to data from the Indian Council of Medical Research (ICMR) and other health bodies, the prevalence of ischemic heart disease doubled from 25.7 million cases in 1990 to over 54.5 million in recent years. Critically, Indians are often diagnosed with heart disease a decade earlier than their Western counterparts, making affordable long-term care a national priority.

Currently, over 500,000 stents are implanted annually in India, with Drug-Eluting Stents (DES) making up nearly 97% of those procedures.

Expert Perspectives: A Divided Heart

While the price caps are a boon for patient affordability, they remain a point of contention within the medical technology industry.

The Case for Quality and Innovation

Industry bodies, such as the Confederation of Indian Industry (CII), have expressed concerns that rigid caps may stifle innovation. “When price becomes the only factor, there is a risk that the latest, most advanced international technologies may not enter the Indian market because the manufacturing and R&D costs exceed the local price ceiling,” says Himanshu Baid, a representative for the medical device industry.

The Case for Patient Rights

On the other side, patient advocacy groups like the All India Drug Action Network (AIDAN) argue that the caps do not go far enough. They have called for “all-inclusive” procedure caps to prevent hospitals from shifting the cost burden to other line items in the bill.

Practical Advice: How to Protect Your Rights

For patients and families facing a cardiac emergency or a planned angioplasty, transparency is the best defense.

1. Request an Itemized Estimate: Before the procedure, ask for a detailed breakdown of costs. Ensure the stent price is listed separately from the hospital’s service charges.

2. Check the NPPA Ceiling: Verify that the price of the stent matches the government-mandated cap (approx. ₹38,933 for DES).

3. Verify the Brand and Batch: Per a 2018 NPPA notification, hospitals are legally required to mention the brand name, manufacturer, and batch number of the stent on the final bill.

4. Use Government Schemes: For those eligible, schemes like Ayushman Bharat (PM-JAY) provide free or highly subsidized cardiac care, including stents.

5. Report Violations: If a hospital refuses to comply with price caps, complaints can be lodged via the NPPA’s Pharma Sahi Daam app or website, or with the State Health Department.

Looking Ahead: The Enforcement Challenge

The reaffirmation of stent caps is a clear signal that the government intends to protect the economic interests of cardiac patients. However, the success of this policy depends on how aggressively state governments use the Clinical Establishments Act to audit private hospital billing.

As the Indian coronary stent market is projected to reach USD 1.3 billion by 2035, the balance between keeping medical technology affordable and ensuring the financial viability of healthcare providers remains one of the most delicate challenges for Indian public health.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• Medical Dialogues. (2026, Feb 15). “Govt Reaffirms NPPA Stent Price Caps; States Tasked with Curbing Hospital Overcharging.” * National Pharmaceutical Pricing Authority (NPPA). (2025, Mar 28). “Revision of Ceiling Price of Coronary Stents.”